Format
Sort by

Send to

Choose Destination

Search results

Items: 7

1.

Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27-28 May, 2016, Rosario, Argentina.

Rosé A, André N, Rozados VR, Mainetti LE, Márquez MM, Rico MJ, Schaiquevich P, Villarroel M, Gregianin L, Graupera JM, García WG, Epelman S, Alasino C, Alonso D, Chantada G, Scharovsky OG.

Ecancermedicalscience. 2016 Sep 6;10:672. doi: 10.3332/ecancer.2016.672. eCollection 2016.

2.

Quality of life in patients with metastatic breast cancer treated with metronomic chemotherapy.

Perroud HA, Alasino CM, Rico MJ, Queralt F, Pezzotto SM, Rozados VR, Scharovsky OG.

Future Oncol. 2016 May;12(10):1233-42. doi: 10.2217/fon-2016-0075. Epub 2016 Mar 7.

PMID:
26948919
3.

Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.

Perroud HA, Alasino CM, Rico MJ, Mainetti LE, Queralt F, Pezzotto SM, Rozados VR, Scharovsky OG.

Cancer Chemother Pharmacol. 2016 Feb;77(2):365-74. doi: 10.1007/s00280-015-2947-9. Epub 2015 Dec 31.

PMID:
26721701
4.

Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer.

Perroud HA, Rico MJ, Alasino CM, Pezzotto SM, Rozados VR, Scharovsky OG.

Indian J Cancer. 2013 Apr-Jun;50(2):115-21. doi: 10.4103/0019-509X.117031.

5.

Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients.

Perroud HA, Rico MJ, Alasino CM, Queralt F, Mainetti LE, Pezzotto SM, Rozados VR, Scharovsky OG.

Future Oncol. 2013 Mar;9(3):451-62. doi: 10.2217/fon.12.196.

PMID:
23469980
6.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

7.

Increased survival with enzalutamide in prostate cancer after chemotherapy.

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators.

N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk